Literature DB >> 22017240

Potential use of exenatide for the treatment of obesity.

Franco Folli1, Rodolfo Guardado Mendoza.   

Abstract

INTRODUCTION: Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in the absence of concomitant pharmacological therapy. Only bariatric surgery provides a means to increase satiety and/or decrease nutrient absorption in obese patients, in the long term. AREAS COVERED: This article reviews the available pharmacological treatments for obesity as well as the pharmacology and mechanism of action of exenatide in obese type 2 diabetic patients. EXPERT OPINION: Exenatide is a potential new candidate treatment for obesity, possibly in combination with other hormones that increase satiety (leptin) and slow gastric emptying (amylin).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017240      PMCID: PMC3495586          DOI: 10.1517/13543784.2011.630660

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  52 in total

Review 1.  New drug targets for the treatment of obesity.

Authors:  A G Powell; C M Apovian; L J Aronne
Journal:  Clin Pharmacol Ther       Date:  2011-06-08       Impact factor: 6.875

Review 2.  An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Authors:  S Madsbad; U Kielgast; M Asmar; C F Deacon; S S Torekov; J J Holst
Journal:  Diabetes Obes Metab       Date:  2011-01-05       Impact factor: 6.577

3.  Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

Authors:  E Rask; T Olsson; S Söderberg; O Johnson; J Seckl; J J Holst; B Ahrén
Journal:  Diabetes Care       Date:  2001-09       Impact factor: 19.112

4.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

5.  Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

Authors:  Richard Bergenstal; Andrew Lewin; Timothy Bailey; Denise Chang; Titus Gylvin; Victor Roberts
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

6.  DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.

Authors:  John B Buse; Daniel J Drucker; Kristin L Taylor; Terri Kim; Brandon Walsh; Hao Hu; Ken Wilhelm; Michael Trautmann; Larry Z Shen; Lisa E Porter
Journal:  Diabetes Care       Date:  2010-03-09       Impact factor: 19.112

7.  Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.

Authors:  Mathijs C Bunck; Michaela Diamant; Bjorn Eliasson; Anja Cornér; Rimma M Shaginian; Robert J Heine; Marja-Riitta Taskinen; Hannele Yki-Järvinen; Ulf Smith
Journal:  Diabetes Care       Date:  2010-04-27       Impact factor: 19.112

8.  Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.

Authors:  Karen Elkind-Hirsch; Ory Marrioneaux; Madhu Bhushan; Denise Vernor; Rajat Bhushan
Journal:  J Clin Endocrinol Metab       Date:  2008-05-06       Impact factor: 5.958

9.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Authors:  David C Klonoff; John B Buse; Loretta L Nielsen; Xuesong Guan; Christopher L Bowlus; John H Holcombe; Matthew E Wintle; David G Maggs
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580

10.  Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Authors:  Eric Ravussin; Steven R Smith; Julie A Mitchell; Reshma Shringarpure; Kevin Shan; Holly Maier; Joy E Koda; Christian Weyer
Journal:  Obesity (Silver Spring)       Date:  2009-06-11       Impact factor: 5.002

View more
  2 in total

1.  Weight loss is still an essential intervention in obesity and its complications: a review.

Authors:  Jianzhong Xiao; Wenying Yang
Journal:  J Obes       Date:  2012-07-02

2.  Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy.

Authors:  Emma Roth; Simon Benoit; Baptiste Quentin; Brian Lam; Sarah Will; Marcella Ma; Nick Heeley; Tamana Darwish; Yashaswi Shrestha; Fiona Gribble; Frank Reimann; Irina Pshenichnaya; Giles Yeo; David J Baker; James L Trevaskis; Clemence Blouet
Journal:  Mol Metab       Date:  2020-11-19       Impact factor: 7.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.